Cargando…
Constitutive reduction in the checkpoint inhibitor, CTLA-4, does not accelerate SLE in NZM 2328 mice
BACKGROUND/OBJECTIVE: Treatment with immune checkpoint inhibitors (ICIs) in oncology patients is increasing. Although ICIs trigger rheumatic immune-related adverse events, development of SLE features has been rare. Whether long-term treatment with ICIs would promote SLE features remains unknown. To...
Autores principales: | Stohl, William, Yu, Ning, Chalmers, Samantha A, Putterman, Chaim, Jacob, Chaim O |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6519407/ https://www.ncbi.nlm.nih.gov/pubmed/31168399 http://dx.doi.org/10.1136/lupus-2018-000313 |
Ejemplares similares
-
Loss of interleukin-1 beta is not protective in the lupus-prone NZM2328 mouse model
por: Loftus, Shannon N., et al.
Publicado: (2023) -
Inhibition of B cell activation following in vivo co-engagement of B cell antigen receptor and Fcγ receptor IIb in non-autoimmune-prone and SLE-prone mice
por: Chu, Seung Y., et al.
Publicado: (2020) -
Conventional DCs from Male and Female Lupus-Prone B6.NZM Sle1/Sle2/Sle3 Mice Express an IFN Signature and Have a Higher Immunometabolism That Are Enhanced by Estrogen
por: Lee, Michael H., et al.
Publicado: (2018) -
Cell-bound complement activation products associate with lupus severity in SLE
por: Arriens, Cristina, et al.
Publicado: (2020) -
CTLA4 as Immunological Checkpoint in the Development of Multiple Sclerosis
por: Gerdes, Lisa Ann, et al.
Publicado: (2016)